Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy

American Heart Journal

Volumn 167, Issue 1, 2014, Pages 43-50

  Nazif, Tamim M ^a,b   Mehran, Roxana ^b,c   Lee, Edwin A M ^a,b   Fahy, Martin ^b   Parise, Helen ^b   Stone, Gregg W ^a,b   Kirtane, Ajay J ^a,b  

^a Department of Medicine   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART CATHETERIZATION; HEART DISEASE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODERATE RISK POPULATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; SCORING SYSTEM; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; AGED; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPENSITY SCORE; TREATMENT OUTCOME; TYROSINE;

EID: 84890116499     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.10.013     Document Type: Article

References (25)

1. S.R. Mehta, C.P. Cannon, and K.A. Fox Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials J Am Coll Cardiol 293 2005 2908 2917
2. A.A. Bavry, D.J. Kumbhani, and A.N. Rassi Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials J Am Coll Cardiol 48 2006 1319 1325
3. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
4. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med 339 1998 436 443
5. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 2002 189 198
6. M. Roffi, D.P. Chew, and D. Mukherjee Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy Eur Heart J 23 2002 1441 1448
7. The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 32 2011 2999 3054
8. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 1920 1959
9. A. Sciahbasi, G. Biondi-Zoccai, and E. Romagnoli Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials Int J Cardiol 155 2012 243 248
10. G.W. Stone, M.E. Bertrand, and J.W. Moses Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial JAMA 297 2007 591 602
11. R.P. Giugliano, J.A. White, and C. Bode Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
12. W.B. Batchelor, T.R. Tolleson, and Y. Huang Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial Circulation 106 2002 1470 1476
13. U. Derhaschnig, C. Pachinger, and B. Jilma Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial Am Heart J 147 2004 E17
14. G.W. Stone, M. Bertrand, and A. Colombo Acute catheterization and urgent intervention triage strategy (ACUITY) trial: study design and rationale Am Heart J 148 2004 764 775
15. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
16. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina N Engl J Med 338 1998 1498 1505
17. X.Q. Zhao, P. Theroux, and S.M. Snapinn Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms) Circulation 100 1999 1609 1615
18. L. Bolognese, G. Falsini, and F. Liistro Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial J Am Coll Cardiol 47 2006 522 528
19. C.M. Gibson, K.P. Singh, and S.A. Murphy Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) Am J Cardiol 94 2004 492 494
20. P. Tricoci, E.D. Peterson, and A.Y. Chen Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE) Am J Cardiol 99 2007 1389 1393
21. T.D. Kinnaird, E. Stabile, and G.S. Mintz Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
22. M. Moscucci, K.A. Fox, and C.P. Cannon Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823
23. S.V. Rao, J.G. Jollis, and R.A. Harrington Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
24. S.V. Rao, K. O'Grady, and K.S. Pieper Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206
25. A. Segev, B.H. Strauss, and M. Tan Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries Am Heart J 150 2005 690 694